Greek Young Oncologists Educational Meeting:
Cancer Pharmacogenetics and Pharmacogenomics
as Tools for Clinical Practice and Research
November 16th 2013, Radisson Blu Park Hotel, Athens-Greece
Meeting Coordinators: Dr Giannis Mountzios, Dr Niki Karahaliou
09:00 – 09:30
Registration
09:30 – 09:45
Introduction/ Welcome
Basic Principles of Cancer Pharmacogenetics
09:45 – 10:15
10:15-10:45
10:45-11:15
Despina Sanoudou (Ass. Professor of Pharmacogenetics, University of Athens School of
Medicine, Visiting Prof. Boston Children’s University Hospital and Harvard School of
Medicine, Athens-Greece)
From Pharmacogenetics to Pharmacogenomics: Evolution and Implications for Clinical
Practice and for Research
Efstathia Giannopoulou (Staff Scientist, Laboratory of Molecular Oncology, Patras
University Hospital, Department of Medicine, University of Patras, Patras-Greece)
Coffee break
Pharmacogenomics as Tools for Diagnosis and Prognosis in Solid Tumors
11:15-11:45
Chara Papadaki (Biologist, University of Crete, Laboratory of Molecular Biology, HeraklionGreece)
Pharmacogenetics and Pharmacogenomics of Molecular Targeted Agents in Oncology
11:45-12:15
12:15-12:45
Niki Karahaliou (Medical Oncologist, Breakthrough Cancer Research Unit, Pangaea Biotech,
Quiron Dexeus, University Hospital, Barcelona, Spain)
Pharmacogenomics as a Tool to Identify New Targets in Oncology and their Impact on
Research
Ken Olaussen (Molecular Biologist, University Paris XI -Paris Sud- and Institut Gustave
Roussy, Paris-France)
12:45-13:00
Discussion
13:00-14:00
Light lunch
14:00-14:30
14:30-15:00
15:00-15:30
15:30-16:00
Breast Cancer Pharmacogenomics: Implications for the Clinic and for Research
Dimitrios Zardavas (Research Fellow, Institut Jules Bordet, Brussels-Belgium)
Lung Cancer Pharmacogenomics as a Tool to Assess Response to Treatment with TKIs
and Emerging Resistance
Rafael Rosell (Medical Oncologist, Catalan Institute of Oncology, Badalona Spain,
Breakthrough Cancer Research Unit, Pangaea Biotech SL Barcelona, Spain)
Coffee break
The Future of Molecular Oncology: Should Every Targeted Agent have its own Biomarker?
Alexandra Voutsina (Molecular Biologist, University of Crete, Laboratory of Molecular
Biology, Heraklion-Greece)
Companion Diagnostics: Promises and Pitfalls
16:00-16:30
Helena Linardou (Ass. Director, Consultant Medical Oncologist, A' Oncology Dept. at
Metropolitan Hospital, Athens-Greece)
16:30-17:00
Discussion & Closing Remarks
17:00-18:00
Young Oncologists Closed Meeting